Canada markets closed

GILD Jun 2023 65.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
4.1500-0.9500 (-18.63%)
As of 03:17PM EDT. Market open.
Full screen
Previous Close5.1000
Expire Date2023-06-16
Day's Range4.1500 - 4.1500
Contract RangeN/A
Open Interest231

    Gilead Sciences: Mother of Three Shares Her CAR T-Cell Therapy Journey: Kelly's Story

    Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck. When the pain progressed to the point where it got worse when she laid down, she asked her husband, an emergency room doctor, what he thought.

  • Reuters

    Gilead widens battle against alleged counterfeit HIV drug ring

    A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged "kingpins." Gilead, which has been pursuing alleged counterfeiters in a civil lawsuit since last year, said in a court filing unsealed on Wednesday it had uncovered an operation that was "staggering in scope," responsible for sales of hundreds of millions of dollars of counterfeit bottles of its top sellers Descovy, Genvoya and Biktarvy, and other medicines. U.S. District Judge Ann Donnelly's latest asset freeze order, also unsealed on Wednesday, targets more than 50 defendants newly added to Gilead's lawsuit.


    Gilead Sciences: WHO Expands Recommendation for Veklury(R) (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline

    Gilead Sciences, Inc. (Nasdaq:GILD) today announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.